pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›tozorakimab
drug · antibody
save

tozorakimab

Phase 3updated 3mo ago
by $AZN ASTRAZENECA PLC🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 3
  • tagPulmonology2 co-mentions · 1 sources
  • tagCOPD2 co-mentions · 1 sources
  • company$AZNASTRAZENECA PLC1 co-mentions · 1 sources

Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.

all catalysts(1)

phase 2 completion · 1
Apr 30, 2026
phase 2 completion
$AZN157.24-0.79%
4mo ago
AstraZeneca Plc — tozorakimab (Phase II Trial Completion)
tozorakimab
→

Trials studying tozorakimab

  • phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbationscompletedn=1,454
  • phase2Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroidsrecruitingn=540
  • phase2A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophilscompletedn=98
  • phase3Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbationsrecruitingn=82
  • phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbationscompletedn=1,132
  • phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.completedn=1,172
  • phase3Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).active not recruitingn=1,713
  • phase1An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimabcompletedn=254
more trials →

News(2)

  • Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
    Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
    biopharma_dive · 16d ago
  • Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
    With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
    biospace · 23d ago
generic
tozorakimab
indication
Acute Respiratory Failure
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 45m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?